We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+21.46%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$270M
AUM Growth
+$101M
Cap. Flow
+$72.1M
Cap. Flow %
26.67%
Top 10 Hldgs %
57.23%
Holding
37
New
8
Increased
17
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$6.55M
2
ILMN icon
Illumina
ILMN
+$5.6M
3
GILD icon
Gilead Sciences
GILD
+$4.99M
4
TSRO
TESARO, Inc.
TSRO
+$4.42M
5
KITE
Kite Pharma, Inc.
KITE
+$3.88M

Top Sells

Rank Stock Value
1
MDRX
Veradigm Inc. Common Stock
MDRX
+$3.76M
2
PACB icon
Pacific Biosciences
PACB
+$1.61M
3
ADVM
Adverum Biotechnologies
ADVM
+$1.13M
4
BPMC
Blueprint Medicines
BPMC
+$828K
5
CRIS icon
Curis
CRIS
+$301K

Sector Composition

Rank Sector Weight
1 Healthcare 81.69%
2 Materials 0.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$28.9M 10.68%
360,000
– –
SAGE
2
DELISTED
Sage Therapeutics
SAGE
$20.3M 7.51%
255,000
– –
FMI
3
DELISTED
Foundation Medicine, Inc.
FMI
$19.1M 7.06%
480,000
– –
BPMC
4
DELISTED
Blueprint Medicines
BPMC
$13.9M 5.15%
275,000
-19,500
-7% -$828K
EVH icon
5
Evolent Health
EVH
$353M
$13.2M 4.88%
520,000
– –
AGIO icon
6
Agios Pharmaceuticals
AGIO
$1.82B
$13.1M 4.85%
255,000
+17,500
+7% +$895K
SGMO
7
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$12.3M 4.56%
1,400,000
+550,000
+65% +$3.53M
CLVS
8
DELISTED
Clovis Oncology, Inc.
CLVS
$12.2M 4.5%
130,000
+107,000
+465% +$6.55M
XBI icon
9
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.62B
$11.6M 4.28%
+150,000
New +$10.6M
ONCE
10
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$10.2M 3.76%
170,000
+35,000
+26% +$1.96M
KITE
11
DELISTED
Kite Pharma, Inc.
KITE
$9.33M 3.45%
90,000
+47,500
+112% +$3.88M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$29.5B
$8.38M 3.1%
105,000
+50,000
+91% +$3.2M
GNMK
13
DELISTED
GenMark Diagnostics, Inc
GNMK
$8.1M 3%
685,000
+285,000
+71% +$3.64M
EPZM
14
DELISTED
Epizyme, Inc
EPZM
$7.85M 2.9%
520,000
+35,000
+7% +$529K
BOLD
15
DELISTED
Audentes Therapeutics, Inc
BOLD
$7.65M 2.83%
400,000
+140,000
+54% +$2.24M
BLUE
16
DELISTED
bluebird bio
BLUE
$6.83M 2.53%
5,018
+3,049
+155% +$3.68M
TSRO
17
DELISTED
TESARO, Inc.
TSRO
$6.71M 2.48%
48,000
+30,500
+174% +$4.42M
VYGR icon
18
Voyager Therapeutics
VYGR
$181M
$6.63M 2.45%
740,000
+240,000
+48% +$2.42M
CDXS icon
19
Codexis
CDXS
$157M
$6.49M 2.4%
1,190,000
+515,000
+76% +$2.37M
GBT
20
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.88M 2.17%
215,000
+113,500
+112% +$3.38M
ILMN icon
21
Illumina
ILMN
$30B
$5.47M 2.02%
+32,382
New +$5.6M
GILD icon
22
Gilead Sciences
GILD
$163B
$5.31M 1.96%
+75,000
New +$4.99M
MYOK
23
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.17M 1.91%
395,000
+130,000
+49% +$1.71M
GILD icon
24
CALL
Gilead Sciences
GILD
$163B
$4.25M 1.57%
+60,000
New +$3.99M
SYRS
25
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$2.93M 1.08%
18,214
– –
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return

Casdin Capital's Q2 2017 Portfolio in Review

As of Q2 2017, Casdin Capital held 37 positions worth $270M, up 59% from $170M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

Casdin Capital deployed $72.1M of net new capital in Q2 2017, opening 8 new positions and adding to 17 existing holdings. Its largest new stake was Illumina: 32,382 shares worth $5.47M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 89% a quarter earlier, followed by Materials.

On the sell side, the largest reduction was Pacific Biosciences, an estimated $1.61M trimmed.

  • Casdin Capital's largest Q2 2017 buy was Illumina: 32,382 shares worth $5.47M.
  • Casdin Capital added most to Clovis Oncology, Inc. in Q2 2017, an estimated $6.55M increase.
  • Casdin Capital's biggest Q2 2017 reduction was Pacific Biosciences, cutting an estimated $1.61M.
  • Casdin Capital fully exited Veradigm Inc. Common Stock in Q2 2017, selling an estimated $3.76M.
  • Casdin Capital's ten largest holdings make up 57% of its $270M portfolio in Q2 2017.
  • Casdin Capital opened 8 new positions and closed 2 in Q2 2017.
  • Casdin Capital's portfolio value rose 59% quarter-over-quarter to $270M.

Based on Casdin Capital's 13F filing for Q2 2017, filed 14 Aug 2017.